Basics Fate Therapeutics, Inc. Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. IPO Date: October 1, 2013 Sector: Healthcare Industry: Biotech Market Cap: $149.02M Activated in VL: True Average Daily Range Avg Daily Range: $0.58 | 3.52% Avg Daily Range (30 D): $0.07 | 5.57% Avg Daily Range (90 D): $0.07 | 5.79% Institutional Daily Volume Avg Daily Volume: .86M Avg Daily Volume (30 D): 1.59M Avg Daily Volume (90 D): 1.87M Trade Size Avg Trade Size (Sh.): 108 Avg Trade Size (Sh.) (30 D): 295 Avg Trade Size (Sh.) (90 D): 299 Institutional Trades Total Inst.Trades: 3,464 Avg Inst. Trade: $2.74M Avg Inst. Trade (30 D): $.85M Avg Inst. Trade (90 D): $1.65M Avg Inst. Trade Volume: .13M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.83M Avg Closing Trade (30 D): $.64M Avg Closing Trade (90 D): $.64M Avg Closing Volume: 204.45K     News May 28, 2025 @ 9:54 PM Fate Therapeutics Announces Phase 1 Data Presentat... Source: N/A Apr 2, 2025 @ 8:01 PM Fate Therapeutics Reports New Employee Inducement ... Source: N/A Feb 28, 2025 @ 6:00 PM NK Cell Therapy Market on Track for Exponential Gr... Source: Delveinsight Nov 29, 2024 @ 6:05 PM Fate Therapeutics Announces Leadership Transition Source: N/A Nov 9, 2024 @ 6:30 PM Fate Therapeutics Highlights Cancer-selective, HER... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.5 $-.32 $-.45 Diluted EPS $-1.5 $-.32 $-.45 Revenue $ 13.34M $ 1.63M $ 1.86M Gross Profit $ $ $ Net Income / Loss $ -175.88M $ -37.62M $ -52.15M Operating Income / Loss $ -200.49M $ -41.28M $ -61.75M Cost of Revenue $ $ $ Net Cash Flow $ -90.22M $ M $ -1.85M PE Ratio